Your browser doesn't support javascript.
loading
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
Ray, Kausik K; Ginsberg, Henry N; Davidson, Michael H; Pordy, Robert; Bessac, Laurence; Minini, Pascal; Eckel, Robert H; Cannon, Christopher P.
Afiliación
  • Ray KK; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Ginsberg HN; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Davidson MH; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Pordy R; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Bessac L; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Minini P; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Eckel RH; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
  • Cannon CP; From Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (K.K.R.); Columbia University, New York, NY (H.N.G.); Department of Medicine, University of Chicago Medicine, Chicago, IL (M.H.D.); Regeneron Pharmaceuticals, Inc Ta
Circulation ; 134(24): 1931-1943, 2016 Dec 13.
Article en En | MEDLINE | ID: mdl-27777279
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Anticuerpos Monoclonales / Anticolesterolemiantes Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circulation Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Anticuerpos Monoclonales / Anticolesterolemiantes Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circulation Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos